Adverse Events of SARS-CoV-2 Therapy: A Pharmacovigilance Study of the FAERS Database.

Viraaj PannuNdausung UdongwoSteven ImburgioAnmol JohalAnton MararenkoHelen PozdniakovaTasnuva AminSwapnil PatelMohammad HossainArman MushtaqEdward LiuJose M FuneJoseph Heaton

Published in: The Annals of pharmacotherapy (2023)

This is the first retrospective study done on reported AEs associated with nirmatrelvir/ritonavir use for COVID-19. COVID-19 and disease recurrence were the most reported AEs. Further monitoring of the FAERS database is warranted to periodically reassess the safety profile of this medication.

Keyphrases

sars cov
adverse drug
coronavirus disease
respiratory syndrome coronavirus
healthcare
emergency department
electronic health record
stem cells
mesenchymal stem cells
cell therapy
drug administration
replacement therapy